Articles citing this paper
Financial costs associated with monopolies on biologic medicines in Australia
Deborah Gleeson A F , Belinda Townsend B , Ruth Lopert C , Joel Lexchin D and Hazel Moir E
+ Author Affiliations
- Author Affiliations
A School of Psychology and Public Health, La Trobe University, Vic. 3068, Australia.
B School of Regulation and Global Governance, College of Asia and the Pacific, Australian National University, ACT 0200, Australia. Email: belinda.townsend@anu.edu.au
C Department of Health Policy and Management, Milken Institute School of Public Health, George Washington University, Washington, DC, USA. Email: rlopert@gwu.edu
D School of Health Policy and Management, York University, 4700 Keele Street, Toronto, Ontario M3J 1P3, Canada. Email: jlexchin@yorku.ca
E Centre for European Studies, College of Arts and Social Sciences, Australian National University, Canberra, ACT 0200, Australia. Email: hazel.moir@anu.edu.au
F Corresponding author. Email: d.gleeson@latrobe.edu.au
Australian Health Review 43(1) 36-42 https://doi.org/10.1071/AH17031
Submitted: 9 February 2017 Accepted: 28 September 2017 Published: 9 November 2017
16 articles found in Crossref database.
Biosimilars are coming: ready or not
Zalcberg John
Internal Medicine Journal. 2018 48(9). p.1027
Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis
Kovitwanichkanont Tom,
Raghunath Sudha,
Wang Dorothy,
Kyi Leo,
Pignataro Silvana,
Morton Susan,
Morand Eric, Leech Michelle
Internal Medicine Journal. 2020 50(3). p.374
What is the impact of intellectual property rules on access to medicines? A systematic review
Tenni Brigitte,
Moir Hazel V. J.,
Townsend Belinda,
Kilic Burcu,
Farrell Anne-Maree,
Keegel Tessa, Gleeson Deborah
Globalization and Health. 2022 18(1).
Trade Agreements and Public Health (2020)
Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions
Khoo Thomas,
Sidhu Navkiran,
Marine Franca,
Lester Susan,
Quinlivan Alannah,
Rowett Debra,
Buchbinder Rachelle, Hill Catherine L.
BMC Rheumatology. 2022 6(1).
Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
Kim Yujeong,
Kwon Hye-Young,
Godman Brian,
Moorkens Evelien,
Simoens Steven, Bae SeungJin
Frontiers in Pharmacology. 2020 11
Personal healthcare costs borne by younger people living with arthritis in Australia: An exploratory observational study
Berkovic Danielle,
Ayton Darshini,
Briggs Andrew M.,
Ademi Zanfina, Ackerman Ilana N.
Health & Social Care in the Community. 2022 30(5).
Factors associated with long‐term healthcare expense and steroid exposure in patients admitted with acute severe ulcerative colitis
Gilmore Robert,
Lo Sheng W.,
Cheong Rachael,
Karim Syeda Tahiya,
Farrah Deborah,
Kashkooli Soleiman,
Segal Jonathan P., Garg Mayur
JGH Open. 2023 7(7). p.482
A Cross-National Comparison of Biosimilars Pricing in Argentina, Australia, Brazil, and Italy
da Silva Machado Fernanda Lacerda,
Cañás Martín,
Urtasun Martín A.,
Marín Gustavo H.,
Albuquerque Flavia Caixeta,
Pont Lisa,
Convertino Irma,
Bonaso Marco,
Tuccori Marco,
Kirchmayer Ursula, Lopes Luciane Cruz
Therapeutic Innovation & Regulatory Science. 2024 58(3). p.549
Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study
Haifer Craig,
Srinivasan Ashish,
An Yoon‐Kyo,
Picardo Sherman,
Langenberg Daniel,
Menon Shankar,
Begun Jakob,
Ghaly Simon, Thin Lena
Medical Journal of Australia. 2021 214(3). p.128
Trade and investment agreements as structural drivers for NCDs: the new public health frontier
Townsend Belinda, Schram Ashley
Australian and New Zealand Journal of Public Health. 2020 44(2). p.92
Monoclonal antibodies and Fc-fusion protein biologic medicines: A multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020
Tong Xinning,
Li Xue,
Pratt Nicole L.,
Hillen Jodie B.,
Stanford Tyman,
Ward Michael,
Roughead Elizabeth E.,
Lai Edward Chia-Cheng,
Shin Ju-Young,
Cheng Franco W.T.,
Peng Kuan,
Lau Chak Sing,
Leung Wai Keung, Wong Ian C.K.
The Lancet Regional Health - Western Pacific. 2022 26 p.100506
Therapeutic equivalence program: continued economic benefits in the context of rising costs and increased demand
Chynoweth Tom, Larmour Ian
Australian Health Review. 2018 43(5). p.585
Safety and efficacy comparisons of rituximab biosimilars to the reference product in patients with cancer: a systematic meta‐analysis review
Song Nina K.,
Musa Hala,
Soriano Michael,
Batger Mellissa,
Hawkins Bryson,
Ramzan Iqbal,
Hibbs David E., Ong Jennifer A.
Journal of Pharmacy Practice and Research. 2022 52(5). p.332
A consensus statement on the use of biosimilar medicines in hematology in Australia
Gregory Gareth P.,
Carrington Christine,
Cheah Chan Y.,
Hawkes Eliza A.,
Irving Ian M.,
Siderov Jim, Opat Stephen
Asia-Pacific Journal of Clinical Oncology. 2020 16(4). p.211
Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?
Williamson Rhys,
Munro Trent,
Ascher David,
Robertson Avril, Pregelj Lisette
Value in Health. 2024 27(3). p.287
